RxDoctor Payments Data

Miriam Cardenas

Family · East Greenwich, RINPI 1942893789

Payments from drug & device makers

$1,707in general payments, 2019–2025

Across 83 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$420
  • Collegium Pharmaceutical, Inc.$308
  • AbbVie$262
  • Novo Nordisk$148
  • Boston Scientific$127
  • Scilex Pharmaceuticals Inc.$123
  • plus $320 from 9 others

What the payments were for

  • Food & beverage$1,707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,707 in reported general payments places this provider in the 80th percentile of 457 family providers in Rhode Island.

See all family providers in Rhode Island

Medicare billing

Part B allowed, 2024
$8,876
Medicare patients
67
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl114$76,218
RelistorMethylnaltrexone Bromide17$41,988
Nurtec OdtRimegepant Sulfate15$16,587
Buprenorphine66$15,610
Xtampza ErOxycodone Myristate26$12,690
OxycontinOxycodone Hcl26$12,562
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen303$10,265
ZtlidoLidocaine16$9,016
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen264$6,246
MovantikNaloxegol Oxalate11$6,085
Oxycodone Hcl284$5,646
Naloxone Hcl73$4,496
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$3,396
Morphine Sulfate ErMorphine Sulfate94$2,132
Lidocaine32$2,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$308$88,907140 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$420$41,98817 claims
Scilex Pharmaceuticals Inc.Ztlido$123$9,01616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 457 family providers in Rhode Island.

Other family in East Greenwich

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →